학술논문
Clinico-Pathological Features, Outcomes and Impacts of COVID-19 Pandemic on Patients with Early-Onset Colorectal Cancer: A Single-Institution Experience
Document Type
article
Author
Daniel Martinez-Perez; David Viñal; Jesús Peña-Lopez; Diego Jimenez-Bou; Iciar Ruiz-Gutierrez; Sergio Martinez-Recio; María Alameda-Guijarro; Antonio Rueda-Lara; Gema Martin-Montalvo; Ismael Ghanem; Ana Belén Custodio; Lucia Trilla-Fuertes; Angelo Gamez-Pozo; Antonio Barbachano; Javier Rodriguez-Cobos; Pilar Bustamante-Madrid; Asuncion Fernandez-Barral; Aurora Burgos; Maria Isabel Prieto-Nieto; Laura Guerra Pastrian; José Manuel González-Sancho; Alberto Muñoz; Jaime Feliu; Nuria Rodríguez-Salas
Source
Cancers, Vol 15, Iss 17, p 4242 (2023)
Subject
Language
English
ISSN
2072-6694
Abstract
Background: The rising incidence of colorectal cancer (CRC) among young patients is alarming. We aim to characterize the clinico-pathological features and outcomes of patients with early-onset CRC (EOCRC), as well as the impacts of COVID-19 pandemic. Methods: We included all patients with pathologically confirmed diagnoses of CRC at Hospital Universitario La Paz from October 2016 to December 2021. The EOCRC cut-off age was 50 years old. Results: A total of 1475 patients diagnosed with CRC were included, eighty (5.4%) of whom had EOCRC. Significant differences were found between EOCRC and later-onset patients regarding T, N stage and metastatic presentation at diagnosis; perineural invasion; tumor budding; high-grade tumors; and signet ring cell histology, with all issues having higher prevalence in the early-onset group. More EOCRC patients had the RAS/ BRAF wild type. Chemotherapy was administered more frequently to patients with EOCRC. In the metastatic setting, the EOCRC group presented a significantly longer median OS. Regarding the COVID-19 pandemic, more patients with COVID-19 were diagnosed with metastatic disease (61%) in the year after the lockdown (14 March 2020) than in the pre-pandemic EOCRC group (29%). Conclusions: EOCRC is diagnosed at a more advanced stage and with worse survival features in localized patients. More patients with EOCRC were diagnosed with metastatic disease in the year after the COVID-19 pandemic lockdown. The long-term consequences of COVID-19 are yet to be determined.